Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
Denmark is known for its high-quality healthcare system, and the pharmaceuticals market plays a crucial role in supporting it.
Customer preferences: The Danish population values access to healthcare services, and the government ensures that healthcare is easily accessible and affordable for all. As a result, the demand for pharmaceutical products is high, with a focus on quality and safety. Customers in Denmark prefer to purchase branded drugs, and there is also a growing trend towards natural and organic remedies.
Trends in the market: The pharmaceuticals market in Denmark is growing, with an increasing focus on research and development. The market is highly regulated, with strict rules on drug approval and pricing. There is a trend towards personalized medicine, with a focus on developing drugs that are tailored to individual patients. Additionally, the COVID-19 pandemic has led to an increased demand for vaccines and other pharmaceutical products.
Local special circumstances: Denmark has a unique healthcare system that is primarily funded by taxes. The government negotiates with pharmaceutical companies to ensure that prices are kept low, and there is a focus on cost-effectiveness. Additionally, there is a high level of collaboration between the government, healthcare providers, and pharmaceutical companies to ensure that patients receive the best possible care.
Underlying macroeconomic factors: Denmark has a strong economy with a high standard of living. The government invests heavily in healthcare and research, creating a favorable environment for the pharmaceuticals market. Additionally, Denmark is home to several pharmaceutical companies, which contributes to the growth of the market. The country's aging population also drives demand for pharmaceutical products, particularly those related to chronic diseases.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)